Phase 3 N=480 Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
Sexual Dysfunctions, Psychological
Primary: Frequency of Adverse Events — 331; 206; 58; 51 participants with any adverse event
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=9 Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer
Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Safety of the Vaccine — 0; 9 participants
Phase 2 N=41 Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma
Primary: Complete Response Rate — 10 percentage of participants
N/A N=17 Efficacy of Dietary Sodium Restriction of Improving Vascular Endothelial Function in Middle Aged and Older Adults
Hypertension
Primary: Improved Flow Mediated Dilation — 3.57; 6.01 percentage dilation
N/A N=23 Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botulinum Neurotoxin for Upper Extremity Spasticity
Upper Extremity Spasticity · Stroke · Acquired Brain Injury
Primary: Change From Baseline in Arm Function Based on Motor Activities Log (MAL-O) — 1.52; 1.79 units on a scale
Phase 4 N=16 24-hour IOP-lowering Effect of 0.01% Bimatoprost
Intraocular Pressure · Glaucoma · Ocular Hypertension
Primary: Nocturnal Intraocular Pressure (IOP) Change — -2.6 mmHg
Phase 3 N=52 Effect of Maraviroc on Endothelial Function in HIV-Infected Patients
HIV Infection · Cardiovascular Disease · Inflammation
Primary: Percent Change in FMD — 0.57; -0.05 percent change in FMD — p=0.17
Phase 2 N=40 The Efficacy and Safety of Hypertonic Saline in Cardiac Surgery Patients.
Coronary Artery Disease · Edema
Primary: Extravascular Lung Water Index — 9; 8; 9; 8 mL/kg
Phase 1 N=82 Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations
Diabetes · Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Injection Pain (VAS mm) — 20.0; 12.8; NA; NA mm
Phase 4 N=58 Improvement of Fluid Balance in Patients Undergoing Surgery of the Colon and Rectum
Colorectal Carcinoma
Primary: Peak Value of I-FABP — 440.8; 522.4 pg/mL
Phase 1 N=14 The Rilpivirine Cerebrospinal-fluid (CSF) Study
HIV
Primary: CSF:Plasma Ratio of Rilpivirine Levels — 1.4 ratio expressed as a percentage
Phase 2 N=34 Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant
Lung Injury, Acute · Respiratory Distress Syndrome, Adult · Bronchiolitis Obliterans
Primary: Percent of Patients With a Greater Than or Equal to 10% Improvement in FEV1, or FVC, and DLCO — 32; 16 percent evaluable participants
Phase 2 N=601 Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
Prevention of Meningococcal Disease
Primary: Percentages of Subjects With hSBA Titers ≥ 1:4 Against N. Meningitidis Serogroups A, C, W, and Y Following 3 Doses of MenACWY Ad+ Vaccine — 6; 0; 93; 81 percentages of…
Phase 4 N=20 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
Macular Edema, Cystoid · Vision Disorders · Diabetic Macular Edema
Primary: Change in the Central Macular Thickness — 85.67; -18.22 Microns
Phase 2 N=24 Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Progression-free Survival at 6 Months — 13.6 percentage of participants